drugset
drugset / Trial / NCT01060722

MOD-4023 Study in Healthy Male Volunteers

NCT01060722 ↗

Phase 1 Completed 24 enrolled OPKO Health, Inc. Tel-Aviv Sourasky Medical Center · collab
RandomizedSingle-groupTriple-blindTreatment

Summary

This study aims to examine the safety, tolerability and pharmacokinetics of a long-lasting Human Growth Hormone (MOD-4023) in healthy volunteers after a single subcutaneous injection at escalating doses.

Timeline

Start
2009-10
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatrogon Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.